Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Conference News AHA 2016

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

L.A. McKeown

November 17, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Caitlin E. Cox

September 08, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Todd Neale

August 04, 2016

News Daily News

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Michael O'Riordan

March 02, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Daily News

Long-term Mortality Worse for Black vs White NSTEMI Patients, Linked with Treatment Discrepancies

July 17, 2014

News Industry News

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

June 11, 2014

Advertisement

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

FDA approves Repatha to treat certain patients with high cholesterol

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Long-term Mortality Worse for Black vs White NSTEMI Patients, Linked with Treatment Discrepancies

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content